OptiBiotix Health Plc (LON:OPTI) a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, CEO Stephen O’Hara talks through the 2016 Investor Presentation. Due to popular demand, the event was held in the Oriental room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 4.30pm with a 4.45pm start.
OptiBiotix Health Plc was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. The aim of the company is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix Health Plc has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
